Berberine‑induced AMPK activation channels proteotoxic stress into adaptive amyloid‑like sequestration via gut‑mediated FXR signaling

Hypothesis

Berberine, through AMPK activation and modulation of the gut microbiome, shifts the cellular response to misfolded proteins from degradation‑centric pathways toward the formation of thermodynamically stable, amyloid‑like aggregates that serve as a protective sequestration mechanism. This adaptive aggregation reduces soluble toxic species, lowers proteostatic burden, and promotes cell survival under chronic metabolic stress.

Mechanistic Rationale

• AMPK activation by berberine (Thr172 phosphorylation) lowers ATP and activates ULK1, initiating autophagy; however, when autophagic flux is overwhelmed, AMPK also phosphorylates and activates transcription factors such as FOXO3 that upregulate molecular chaperones and components of the amyloid‑forming machinery (e.g., transglutaminase 2) Berberine activates AMPK via phosphorylation at Thr172.
• Gut microbiome shifts induced by berberine increase Akkermansia muciniphila and SCFA‑producing bacteria, enhancing intestinal FXR signaling. FXR activation in hepatocytes and intestinal epithelial cells promotes expression of bile‑acid‑detoxifying enzymes and also upregulates genes involved in protein quality control, including Hsp70 and small heat‑shock proteins that favor ordered aggregation over amorphous clumps Berberine increases beneficial species like Akkermansia muciniphila.
• The combined AMPK‑FXR axis biases the proteostasis network toward a controlled phase‑separation process where misfolded proteins are redirected into β‑sheet‑rich, amyloid‑like deposits. These deposits are less prone to nucleation‑dependent toxicity and can be safely cleared later by specialized autophagy receptors (e.g., p62) when capacity recovers.
• Consequently, dissolving these aggregates with conventional disaggregases (e.g., HSP104 analogs) would remove a protective depot, increasing soluble oligomer levels and exacerbating cellular stress—a prediction opposite to the usual view that aggregates are merely pathogenic.

Testable Predictions

1. Aggregate phenotype – In hepatocytes or neuronal cells treated with berberine under proteotoxic stress (e.g., tunicamycin or amyloid‑β exposure), insoluble fractions will show increased thioflavin‑T positivity and resistance to SDS, indicating ordered amyloid‑like aggregates, while soluble oligomer levels decrease.
2. Dependence on AMPK and FXR – Genetic knockdown of AMPKα1/2 or FXR will abolish berberine‑induced aggregate formation and revert the phenotype to increased soluble toxic species and heightened apoptosis.
3. Microbiome mediation – Germ‑free mice or antibiotic‑treated mice receiving berberine will fail to develop the protective aggregate signature and will exhibit worse metabolic and proteostatic outcomes compared with conventionally colonized counterparts.
4. Functional consequence – Acute pharmacological dissolution of berberine‑induced aggregates (using a low‑dose HSP70 inducer that preferentially solubilizes amyloids) will raise cytosolic oligomer concentrations, increase caspase‑3 activation, and impair insulin signaling, despite unchanged AMPK activity.
5. In vivo relevance – Aging mice fed a berberine‑supplemented diet will display higher hepatic amyloid‑like deposits (detected by filter‑trap assay) concomitant with improved glucose tolerance and reduced liver inflammation, whereas AMPK‑deficient littermates will not.

Experimental Approach

• Cell culture: Treat HepG2 and SH‑SY5Y cells with berberine (10‑25 µM) ± proteasome inhibitor MG132. Assess aggregate formation via filter‑trap, ThT fluorescence, and electron microscopy. Modulate AMPK (Compound C) or FXR (glycocholic acid antagonist) and repeat.
• Microbiome experiments: Colonize germ‑free mice with berberine‑altered microbiota or use fecal microbiota transfer; compare aggregate markers in liver and brain.
• Intervention studies: Administer an amyloid‑solubilizing peptide (e.g., KLVFF) after berberine pretreatment; measure soluble oligomers (dot‑blot with A11 oligomer antibody), cell viability (MTT), and inflammatory cytokines (ELISA).
• In vivo metabolic phenotyping: GTT, ITT, lipid panels, and histology (H&E, Oil‑Red‑O) in wild‑type vs. AMPK‑LKO mice on berberine diet for 12 weeks.

Falsifiability

If berberine treatment does not increase ordered amyloid‑like deposits, does not reduce soluble toxic oligomers, or if aggregate dissolution improves rather than worsens cellular health under the above conditions, the hypothesis is refuted. Conversely, consistent confirmation across the outlined assays would support the notion that berberine redirects proteotoxic stress into a sequestered, amyloid‑like state as a adaptive survival strategy.